Get the Stockscreener App
3.335
2.31%
0.085
Rocket Pharmaceuticals Inc stock is traded at $3.335, with a volume of 687.41K.
It is up +2.31% in the last 24 hours and up +8.31% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.25
Open:
$3.27
24h Volume:
687.41K
Relative Volume:
0.22
Market Cap:
$364.16M
Revenue:
-
Net Income/Loss:
$-209.38M
P/E Ratio:
-1.777
EPS:
-1.8768
Net Cash Flow:
$-179.81M
1W Performance:
-3.90%
1M Performance:
+8.31%
6M Performance:
-4.45%
1Y Performance:
+31.43%
1-Day Range:
$3.20
$3.39
1-Week Range:
$3.075
$3.63
52-Week Range:
$2.40
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.335 | 354.88M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
493.64 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.48 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
896.55 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.21 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.23 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM: RCKT) added to Russell Microcap Index - marketscreener.com
Rocket Pharmaceuticals, Inc. (RCKT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 11, 2025 - The National Law Review
Price to earnings forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Price to sales forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
Rocket Pharma updates cash position after selling priority review voucher - MSN
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Price to sales forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT - TradingView
Rocket Pharmaceuticals, Inc. Actuals & Estimates (HAM:9IP1) - TradingView
Rocket Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:9IP1) - TradingView
Price to sales forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1 - TradingView
RCKT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1 - TradingView
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone? - Insider Monkey
Price to book forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT - TradingView
Enterprise value to EBIT forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT - TradingView
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT - TradingView
Price to book forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1 - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1 - TradingView
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Institutional Confidence - TradingKey
ROCKET PHARMACEUTICALS INC (RCKT) Stock Chart - ChartMill
Rocket Pharmaceuticals analyst consensus stays supportive, shares trade near recent lows - AD HOC NEWS
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Rocket Pharmaceuticals Inc (RCKTW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Can Rocket Pharmaceuticals (NASDAQ:RCKT) Afford To Invest In Growth? - Moomoo
Rocket Pharmaceuticals Inc (RCKTW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rocket Pharmaceuticals Inc - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Institutional Confidence - TradingKey
Rocket Pharmaceuticals Delivers Bold Moves Amid Volatile Market - timothysykes.com
Rocket Pharmaceuticals Inc (RCKTW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass - MedCity News
Rocket Pharma closes sale of PRV for $180 million - The Pharma Letter
Rocket Pharmaceuticals (RCKT) Secures Over $320M Following PRV S - GuruFocus
Rocket Pharmaceuticals (RCKT) Secures $180M from Rare Disease Vo - GuruFocus
Rocket Pharmaceuticals Closes $180 Million Priority Review Voucher Sale - grafa.com
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):